Lercanidipina Mylan

Lercanidipine, the active ingredient in Lercanidipina Mylan, is a calcium channel blocker presented as an oral tablet for systemic use. It is prescribed to lower elevated blood pressure in adult patients with hypertension and is marketed in the European Union.\n\nGNH India supplies Lercanidipina Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing consistent quality and regulatory compliance.

Lercanidipine is a dihydropyridine calcium‑channel blocker used to manage arterial hypertension.\n\nHypertension: reduces systolic and diastolic blood pressure by causing arterial vasodilation, helping to achieve target blood pressure levels.

Lercanidipine may cause a range of adverse reactions, most of which are mild and reversible.\n\nCommon Side Effects:\n- Headache\n- Flushing\n- Peripheral edema\n- Dizziness\n- Tachycardia\n- Palpitations\n\nSerious or Rare Side Effects:\n- Angioedema\n- Severe hypotension\n- Myocardial infarction\n- Hepatic dysfunction\n- Severe allergic reactions\n- Neutropenia

Before initiating therapy, clinicians should consider several safety aspects.\n\nMonitor blood pressure: ensure adequate control without excessive hypotension.\nAssess hepatic function: use caution in patients with liver impairment.\nAvoid abrupt discontinuation: taper to prevent rebound hypertension.\nReview concomitant antihypertensives: adjust doses to avoid additive effects.\nStore at ambient temperature: keep in the original packaging, protect from moisture.

Lercanidipine can interact with several drug classes, requiring careful management.\n\nMajor Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels.\n- Concomitant use with other calcium‑channel blockers: risk of additive hypotension.\n- Grapefruit juice: can markedly raise drug exposure.\n- Other potent antihypertensives: may cause severe blood pressure drops.\n\nModerate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.\n- Diuretics: may enhance hypotensive effect.\n- Beta‑blockers: possible additive bradycardia.\n- NSAIDs: may attenuate antihypertensive response.